{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-004910","form_type":"8-K","ticker":"MNPR","cik":"0001645469","company_name":"Monopar Therapeutics","filed_at":"2025-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.290560+00:00","generated_at":"2026-05-26T05:55:46.423634+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Monopar board: Michael Brown resigns, Lavina Talukdar appointed","bullets":["Michael J. Brown resigned from the Board effective February 19, 2025.","Lavina Talukdar appointed to the Board effective February 21, 2025.","Talukdar also named to Audit, Compensation, Governance, and Plan Administration Committees.","Talukdar is SVP, Head of Investor Relations at Moderna, with 20+ years of experience.","She will receive standard compensation for non-employee directors."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-004910","json":"https://secwatch.observer/filing/0001437749-25-004910.json","markdown":"https://secwatch.observer/filing/0001437749-25-004910.md","text":"https://secwatch.observer/filing/0001437749-25-004910.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645469/000143774925004910/0001437749-25-004910-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645469/000143774925004910/mnpr20250221_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T05:55:46.423634+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3c355e8482","claim":"Lavina Talukdar was appointed as Director at Monopar Therapeutics.","evidence_excerpt":"On February 21, 2025, the Company’s Board appointed Lavina Talukdar to the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774925004910/0001437749-25-004910-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"e33f0de8a2","claim":"Michael J. Brown resigned as Director at Monopar Therapeutics.","evidence_excerpt":"Michael J. Brown has resigned from his position as a member of the Monopar Therapeutics Inc. (the” Company”) Board of Directors (the “Board”) effective February 19, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774925004910/0001437749-25-004910-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}